CABOMETYX® (Cabozantinib)

The FDA on September 17, 2021, approved CABOMETYX® (Cabozantinib) for adult and pediatric patients 12 years of age and older with locally advanced or metastatic Differentiated Thyroid Cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are ineligible or refractory to Radioactive Iodine. CABOMETYX® is a product of Exelixis, Inc.